DDInter1055 DDInter915
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) upregulates {v} (Gene) FKBP14
FKBP14 {u} (Gene) is upregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) resembles {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) is associated with {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) upregulates {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Levofloxacin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Levofloxacin (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) resembles asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Indacaterol (Compound)
Levofloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is associated with ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Levofloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) upregulates UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Indacaterol (Compound)